A test that monitors blood levels of DNA fragments released by dying tumor cells may serve as an accurate early indicator of treatment success in late stages of melanoma.
In his new book, “No More Tears: The Dark Secrets of Johnson & Johnson,” Gardiner Harris, who was previously the public health and pharmaceutical business reporter for The New York Times, talks about the history of the overuse of red blood cell growth factors in oncology.
